oral glp-1 medications fda approved In a major milestone for obesity care, the has Wegovy® as the first receptor agonist for chronic weight management in adults with obesity or overweight and related conditions GLP-1 Safety Check - National

Diabetes Obes Metab 22(3):355364 Ruiz PLD, Stene LC, Bakken IJ, Hberg SE, Birkeland KI, Gulseth HL (2018) Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study

Key features of retatrutide include: Acts as a triple agonist on GLP-1, GIP, and glucagon

Tirzepatide is unique as a dual GIP and GLP-1 receptor agonist

Mechanism of Action Glucose Homeostasis: Enhances insulin secretion, suppresses glucagon release Gastric Motility: Delays emptying, promotes satiety signals Cardiovascular: Improves endothelial function, reduces inflammation Neuroprotection: Activates survival pathways, reduces neuroinflammation Renal Protection: Reduces albuminuria, preserves kidney function Hepatic: Improves steatosis, reduces liver inflammation Research Advantages Extended Half-Life: Hours vs

The result is a decrease in ectopic fat storagea hallmark of insulin resistance and NAFLD

Alright, thats enough political stuff you guys probably get enough of that elsewhere